Healthcare provider profile · identity verified

Daniel Joseph Bodnar, D.O.

Family Practice · LATROBE, PA · NPI 1184111361

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Levothyroxine Sodium	Levothyroxine Sodium	665	189
Atorvastatin Calcium	Atorvastatin Calcium	499	164
Simvastatin	Simvastatin	451	129
Amlodipine Besylate	Amlodipine Besylate	443	131
Pantoprazole Sodium	Pantoprazole Sodium	416	133
Lisinopril	Lisinopril	376	126
Losartan Potassium	Losartan Potassium	327	94
Gabapentin	Gabapentin	296	78
Metoprolol Succinate	Metoprolol Succinate	279	86
Sertraline Hcl	Sertraline Hcl	252	78
Ozempic	Semaglutide	247	46
Albuterol Sulfate Hfa	Albuterol Sulfate	240	75
Prednisone	Prednisone	234	130
Tamsulosin Hcl	Tamsulosin Hcl	225	66
Omeprazole	Omeprazole	223	74
Metformin Hcl	Metformin Hcl	213	64
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	211	77
Furosemide	Furosemide	199	74
Hydrochlorothiazide	Hydrochlorothiazide	184	60
Escitalopram Oxalate	Escitalopram Oxalate	182	62
Metoprolol Tartrate	Metoprolol Tartrate	181	54
Trazodone Hcl	Trazodone Hcl	181	48
Jardiance	Empagliflozin	173	38
Rosuvastatin Calcium	Rosuvastatin Calcium	152	51
Celecoxib	Celecoxib	137	39
Lorazepam	Lorazepam	132	46
Azithromycin	Azithromycin	124	88
Synthroid	Levothyroxine Sodium	119	28
Duloxetine Hcl	Duloxetine Hcl	118	36
Pravastatin Sodium	Pravastatin Sodium	118	29
Clopidogrel	Clopidogrel Bisulfate	113	29
Xarelto	Rivaroxaban	112	26
Famotidine	Famotidine	108	33
Finasteride	Finasteride	108	32
Irbesartan	Irbesartan	107	32
Allopurinol	Allopurinol	106	29
Citalopram Hbr	Citalopram Hydrobromide	106	27
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	103	61
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	92	26
Metformin Hcl Er	Metformin Hcl	91	25
Carvedilol	Carvedilol	88	21
Alprazolam	Alprazolam	87	20
Spiriva Respimat	Tiotropium Bromide	83	18
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	82	21
Amoxicillin	Amoxicillin	80	60
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	78	28
Eliquis	Apixaban	72	20
Tramadol Hcl	Tramadol Hcl	71	31
Ropinirole Hcl	Ropinirole Hcl	69	suppressed
Repaglinide	Repaglinide	67	suppressed
Fluticasone Propionate	Fluticasone Propionate	66	28
Buspirone Hcl	Buspirone Hcl	62	20
Ondansetron Odt	Ondansetron	61	28
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	57	13
Bumetanide	Bumetanide	57	13
Zolpidem Tartrate	Zolpidem Tartrate	57	14
Breo Ellipta	Fluticasone/Vilanterol	56	12
Amitriptyline Hcl	Amitriptyline Hcl	55	16
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	54	12
Meloxicam	Meloxicam	54	14
Montelukast Sodium	Montelukast Sodium	53	17
Potassium Chloride	Potassium Chloride	53	16
Mirtazapine	Mirtazapine	52	16
Warfarin Sodium	Warfarin Sodium	51	11
Valsartan	Valsartan	49	19
Ibuprofen	Ibuprofen	48	21
Alendronate Sodium	Alendronate Sodium	46	16
Doxycycline Hyclate	Doxycycline Hyclate	46	35
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	46	11
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	44	14
Toujeo Solostar	Insulin Glargine,hum.Rec.Anlog	44	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	44	28
Clonazepam	Clonazepam	43	suppressed
Glimepiride	Glimepiride	43	11
Oxycodone Hcl	Oxycodone Hcl	42	17
Oxybutynin Chloride Er	Oxybutynin Chloride	41	12
Fluoxetine Hcl	Fluoxetine Hcl	40	12
Atenolol	Atenolol	39	17
Bupropion Xl	Bupropion Hcl	38	14
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	38	13
Tradjenta	Linagliptin	38	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	38	11
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	37	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	36	13
Ketoconazole	Ketoconazole	36	21
Midodrine Hcl	Midodrine Hcl	36	suppressed
Bupropion Hcl Sr	Bupropion Hcl	35	14
Esomeprazole Magnesium	Esomeprazole Magnesium	35	suppressed
Ventolin Hfa	Albuterol Sulfate	34	11
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	33	27
Donepezil Hcl	Donepezil Hcl	33	suppressed
Incruse Ellipta	Umeclidinium Bromide	33	suppressed
Levofloxacin	Levofloxacin	33	26
Irbesartan-Hydrochlorothiazide	Irbesartan/Hydrochlorothiazide	32	suppressed
Meclizine Hcl	Meclizine Hcl	32	16
Cephalexin	Cephalexin	31	26
Linzess	Linaclotide	31	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	31	20
Primidone	Primidone	30	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	28	suppressed
Raloxifene Hcl	Raloxifene Hcl	28	suppressed
Paroxetine Hcl	Paroxetine Hcl	27	suppressed
Valacyclovir	Valacyclovir Hcl	27	15
Baclofen	Baclofen	26	suppressed
Farxiga	Dapagliflozin Propanediol	26	suppressed
Ondansetron Hcl	Ondansetron Hcl	25	12
Glipizide	Glipizide	24	suppressed
Trulicity	Dulaglutide	24	suppressed
Fenofibrate	Fenofibrate	23	suppressed
Hydroxyzine Pamoate	Hydroxyzine Pamoate	23	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	23	suppressed
Fludrocortisone Acetate	Fludrocortisone Acetate	22	suppressed
Spironolactone	Spironolactone	22	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	21	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	21	suppressed
Januvia	Sitagliptin Phosphate	21	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	20	17
Doxazosin Mesylate	Doxazosin Mesylate	20	suppressed
Humalog Kwikpen U-100	Insulin Lispro	20	suppressed
Ibu	Ibuprofen	20	suppressed
Myrbetriq	Mirabegron	20	suppressed
Sucralfate	Sucralfate	20	11
Tizanidine Hcl	Tizanidine Hcl	20	suppressed
Clonidine Hcl	Clonidine Hcl	19	suppressed
Folic Acid	Folic Acid	19	suppressed
Ofloxacin	Ofloxacin	19	15
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	19	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	18	suppressed
Glipizide Er	Glipizide	17	suppressed
Nystatin	Nystatin	17	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	17	suppressed
Diclofenac Sodium	Diclofenac Sodium	16	suppressed
Humulin 70/30 Kwikpen	Insulin Nph Hum/Reg Insulin Hm	16	suppressed
Mounjaro	Tirzepatide	16	suppressed
Nadolol	Nadolol	16	suppressed
Sotalol	Sotalol Hcl	16	suppressed
Ezetimibe	Ezetimibe	15	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	15	suppressed
Levetiracetam	Levetiracetam	15	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	15	15
Quetiapine Fumarate	Quetiapine Fumarate	15	suppressed
Topiramate	Topiramate	15	suppressed
Hydrocortisone	Hydrocortisone	14	suppressed
Prolia	Denosumab	14	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	13	suppressed
Droplet Pen Needle	Pen Needle, Diabetic	13	suppressed
Novolog Flexpen	Insulin Aspart	13	suppressed
Novolog Mix 70-30 Flexpen	Insulin Aspart Prot/Insuln Asp	13	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	13	suppressed
Terazosin Hcl	Terazosin Hcl	13	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	13	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	13	suppressed
Dilt-Xr	Diltiazem Hcl	12	suppressed
Fluconazole	Fluconazole	12	suppressed
Lamotrigine	Lamotrigine	12	suppressed
Metronidazole	Metronidazole	12	suppressed
Ultra-Fine Micro Pen Needle	Pen Needle, Diabetic	12	suppressed
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	11	suppressed
Captopril	Captopril	11	suppressed
Cefuroxime	Cefuroxime Axetil	11	suppressed
Methylprednisolone	Methylprednisolone	11	11
Movantik	Naloxegol Oxalate	11	suppressed
Naproxen	Naproxen	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error